UNLIMITED TURBO LONG - ELI LILLY & CO | Market Closed - Deutsche Boerse AG 03:50:22 2024-06-10 pm EDT | ||
| 57.05 EUR | +2.57% |
|
| Current month | +8.85% | ||
| 1 month | +19.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-10 | 57.05 | +2.57% |
| 24-06-07 | 55.62 | +3.13% |
| 24-06-06 | 53.93 | +0.54% |
| 24-06-05 | 53.64 | -0.02% |
| 24-06-04 | 53.65 | +0.66% |
Delayed Quote Deutsche Boerse AG
Last update June 10, 2024 at 03:50 pm EDT
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PH22JF |
| ISIN | DE000PH22JF2 |
| Date issued | 2021-06-30 |
| Strike | 250.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.05 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 57.28 € |
|---|---|
| Lowest since issue | 1.31 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
865
USD
Average target price
855.2
USD
Spread / Average Target
-1.14%
- Stock Market
- Certificates
- Certificat
